PTC Therapeutics: director Glenn Steele Jr sold 12,000 shares

What happened

• Glenn Steele Jr, director, exercised options to acquire 12,000 shares at $11.23 for $134,760 and on the same date sold 12,000 shares at $65.16 for $781,920 (both Sep 30, 2026). The Form 4 also reports an exercise/conversion of a derivative for 12,000 shares reported with $0.00 consideration (disposed).

Key details

• Transaction dates and prices: Sep 30, 2026 — exercised 12,000 shares at $11.23 (code M) and sold 12,000 shares at $65.16 (code S); also a derivative exercise/conversion of 12,000 shares at $0.00 (code M, disposed).
• Shares owned after the transaction: not stated in the filing.
• Footnotes: the sale was effected pursuant to a written Rule 10b5-1 plan adopted Mar 9, 2026 (F1); the options were currently exercisable (F2).
• Filing date and timeliness: Form filed Oct 2, 2026; no late filing is indicated in the report.

Why it may matter

• The filing shows an option exercise (M) and an immediate sale (S) of the same 12,000 shares on Sep 30, 2026, indicating the shares were sold at once after exercise. It also reports a derivative conversion/exercise with $0.00 consideration.
• The filing states the sale was made under a Rule 10b5-1 plan adopted Mar 9, 2026.
• A filing does not show why the insider traded or why the company acted.